Clinical trial
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies…
NCT00372710 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00372710 |
|---|---|
| Title | Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions |
| Official title | Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer With Bone Metastasis |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 30 |
| Start date | Aug 1, 2002 |
| First posted | Sep 7, 2006 |
| Last update posted | Nov 23, 2009 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: